» Articles » PMID: 33096754

Development of Radiotracers for Breast Cancer-The Tumor Microenvironment As an Emerging Target

Overview
Journal Cells
Publisher MDPI
Date 2020 Oct 24
PMID 33096754
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular imaging plays an increasingly important role in the diagnosis and treatment of different malignancies. Radiolabeled probes enable the visualization of the primary tumor as well as the metastases and have been also employed in targeted therapy and theranostic approaches. With breast cancer being the most common malignancy in women worldwide it is of special interest to develop novel targeted treatments. However, tumor microenvironment and escape mechanisms often limit their therapeutic potential. Addressing tumor stroma associated targets provides a promising option to inhibit tumor growth and angiogenesis and to disrupt tumor tissue architecture. This review describes recent developments on radiolabeled probes used in diagnosis and treatment of breast cancer especially in triple negative type with the focus on potential targets offered by the tumor microenvironment, like tumor associated macrophages, cancer associated fibroblasts, and endothelial cells.

Citing Articles

Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model.

Piranfar A, Moradi Kashkooli F, Zhan W, Bhandari A, Saboury B, Rahmim A NPJ Syst Biol Appl. 2024; 10(1):39.

PMID: 38609421 PMC: 11015041. DOI: 10.1038/s41540-024-00362-4.


Synthesis of a [F]F Estradiol Derivative via Click Chemistry Using an Automated Synthesis Module: In Vitro Evaluation as Potential Radiopharmaceutical for Breast Cancer Imaging.

Tejeria M, Pereira M, Gambini J, Duarte P, Giglio J, Rey A Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543174 PMC: 10975010. DOI: 10.3390/ph17030388.


Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.

Castorina L, Comis A, Prestifilippo A, Quartuccio N, Panareo S, Filippi L J Clin Med. 2024; 13(1).

PMID: 38202160 PMC: 10779934. DOI: 10.3390/jcm13010154.


Estimation of relative biological effectiveness of Ac compared to Lu during [Ac]Ac-PSMA and [Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS.

Rumiantcev M, Li W, Lindner S, Liubchenko G, Resch S, Bartenstein P EJNMMI Phys. 2023; 10(1):53.

PMID: 37695374 PMC: 10495309. DOI: 10.1186/s40658-023-00567-2.


The Role of PET/CT in Breast Cancer.

Hadebe B, Harry L, Ebrahim T, Pillay V, Vorster M Diagnostics (Basel). 2023; 13(4).

PMID: 36832085 PMC: 9955497. DOI: 10.3390/diagnostics13040597.


References
1.
Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D . A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018; 59(9):1423-1429. PMC: 6126438. DOI: 10.2967/jnumed.118.210435. View

2.
Biswas S, Allavena P, Mantovani A . Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013; 35(5):585-600. DOI: 10.1007/s00281-013-0367-7. View

3.
Sorensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V . Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. Theranostics. 2016; 6(2):262-71. PMC: 4729774. DOI: 10.7150/thno.13502. View

4.
Santos A, Jung J, Aziz N, Kissil J, Pure E . Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009; 119(12):3613-25. PMC: 2786791. DOI: 10.1172/JCI38988. View

5.
Ataollahi M, Sharifi J, Paknahad M, Paknahad A . Breast cancer and associated factors: a review. J Med Life. 2017; 8(Spec Iss 4):6-11. PMC: 5319297. View